GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (LTS:0JDK) » Definitions » Profitability Rank

Iovance Biotherapeutics (LTS:0JDK) Profitability Rank : 1 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Iovance Biotherapeutics Profitability Rank?

Iovance Biotherapeutics has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Iovance Biotherapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -25,156.85%. As of today, Iovance Biotherapeutics's Piotroski F-Score is 4.


Competitive Comparison of Iovance Biotherapeutics's Profitability Rank

For the Biotechnology subindustry, Iovance Biotherapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iovance Biotherapeutics's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's Profitability Rank falls into.



Iovance Biotherapeutics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Iovance Biotherapeutics has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Iovance Biotherapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-121.256 / 0.482
=-25,156.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Iovance Biotherapeutics has an F-score of 4 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Iovance Biotherapeutics Profitability Rank Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Iovance Biotherapeutics (LTS:0JDK) Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Iovance Biotherapeutics (LTS:0JDK) Headlines

No Headlines